Application of soluble PD-L2 as SLE biomarker

A technology of PD-L2 and biomarkers, which is applied in the application field of soluble PD-L2 as SLE biomarkers, can solve the problems of difficult early diagnosis and repeated and changeable disease, and achieve improved diagnosis and treatment effect, high diagnosis and treatment value, good The effect of clinical application prospect

CN111337685APending Publication Date: 2020-06-26SUZHOU HEALTH COLLEGE
1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2020-06-26

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses an application of soluble PD-L2 as an SLE biomarker, and particularly discloses an application of soluble PD-L2 as an SLE biomarker in preparation of an SLE diagnosis and treatment evaluation reagent, and a detection sample of the diagnosis and treatment evaluation reagent is serum. Meanwhile, the invention discloses application of the reagent group in preparation of an SLEdiagnosis and treatment evaluation reagent, the reagent group comprises a soluble PD-L2 detection reagent and complement C3 and C4 detection reagents, and the soluble PD-L2 level is positively correlated with the complement C3 and C4 levels. The detection kit is used for combined detection of soluble PD-L2 and complement C3 and C4 in a serum sample, can be effectively used for early diagnosis andprognosis evaluation of SLE diseases, provides a new approach for diagnosis and treatment of the SLE diseases, and has good clinical application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of biological detection, and in particular relates to the application of soluble PD-L2 (sPD-L2) as an SLE biomarker. Background technique

[0002] SLE is a rheumatic autoimmune disease, and its clinical manifestations can involve various organs and tissues in the whole body. It is a systemic and diffuse disease. SLE tends to occur in young women, usually 20-40 years old women of childbearing age. In the pathogenesis of SLE, autoimmune tolerance impairment, autoantibody production and inflammatory cell infiltration caused by excessive activation of lymphocytes are the main pathological damage mechanisms. In the immunopathological process of SLE, the B7 / CD28 family molecular signaling pathway plays an important role. It can not only initiate, enhance and maintain the immune response mediated by T and B lymphocytes by providing positive co-stimulatory signals, but also through Provides negative co-stimulatory...

Examples

Embodiment Construction

[0021] The present invention will be further described below in conjunction with specific examples, but the examples are only exemplary and do not constitute any limitation to the scope of the present invention. Those skilled in the art should understand that the details and forms of the technical solutions of the present invention can be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the protection scope of the present invention.

[0022] 1 Materials and methods

[0023] 1.1 Research object

[0024] The peripheral blood serum of 78 SLE patients came from the Laboratory Department of Suzhou Hospital of Traditional Chinese Medicine, and the collection time was from January 2013 to July 2015. Serum was collected and frozen in -80°C refrigerator for later use. The normal healthy control group came from the healthy people who underwent physical examination in Wuzhong People's Hos...